Xbrane Biopharma AB 

Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden.